Partial
Partially Aligned
Patient Risk:
Low
Summary
The response includes some on-label indication statements for schizophrenia and adjunctive MDD and a general mechanism claim, but it adds multiple sales/earnings figures and trial effectiveness claims that are not supported by the provided FDA label excerpts.
Category Scores
Accurate Statements
Rexulti is indicated for the treatment of schizophrenia in adults.
Supported by Indications and Usage (Section 1): “Treatment of schizophrenia in adults and pediatric patients ages 13 years and older.”
Rexulti is indicated as an adjunctive treatment for major depressive disorder in adults.
Supported by Indications and Usage (Section 1): “Adjunctive treatment to antidepressants for major depressive disorder (MDD) in adults.”
Unsupported Statements
Rexulti works by affecting dopamine and serotonin receptors in the brain.
No mechanism-of-action statement related to dopamine/serotonin receptors is included in the provided label excerpts (Sections 1, 5.1, 5.2, 6, 8.5 and Medication Guide text provided).
In 2023, Rexulti generated $1.5 billion in sales for the full year 2023.
No sales/revenue figures are present in the provided FDA labeling excerpts.
In the fourth quarter of 2023, Rexulti achieved sales of $386 million.
No sales/revenue figures are present in the provided FDA labeling excerpts.
Clinical trials have demonstrated Rexulti's effectiveness in treating schizophrenia.
No efficacy/clinical trial outcome statements for schizophrenia are included in the provided label excerpts (Section 14.3 is referenced in the prompt only for agitation PRN limitation, but no trial effectiveness details were provided).
Clinical trials have demonstrated Rexulti's effectiveness as an add-on therapy for major depressive disorder.
No efficacy/clinical trial outcome statements for adjunctive MDD are included in the provided label excerpts.
Contradictions
Important Omissions
No boxed warning or major safety restriction content was mentioned (e.g., increased mortality in elderly patients with dementia-related psychosis; not approved for dementia-related psychosis without agitation associated with Alzheimer’s disease; and increased risk of suicidal thoughts/behaviors).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The response does not include contraindications or dosing/safety instructions. However, it omits major boxed-warning safety information present in the provided label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Non-label-supported claims (sales figures, mechanism-of-action details, and generalized clinical trial effectiveness statements) plus omission of boxed-warning safety information.
Suggested Improvement
Limit claims to the provided label-supported content (e.g., Indications and Usage). Avoid revenue figures and generalized trial-effectiveness statements unless the specific label efficacy evidence is provided; include key boxed-warning safety restrictions from Sections 5.1/8.5 and 5.2/Medication Guide when discussing Rexulti.